When you have a low mosaic embryo, you may need to decide whether to transfer it before or after your other embryos, or whether to consider another egg collection first.

The mosaic level is part of that decision, but it is only one part.

Transfer priority also depends on the chromosome involved, embryo grading, the other embryos available and the realistic prospect of creating more embryos.

What “low mosaic” means on your PGT-A report

A mosaic result means the biopsy contained a mixture of chromosome findings.

Some of the cells tested appeared to have the expected number of chromosomes, while others showed extra or missing chromosome material.

A low mosaic result means the biopsy contained a small amount of abnormal chromosome material, more than would usually be seen in a euploid result but less than in a high mosaic result.

“Low” refers to the estimated proportion of the abnormal finding within the biopsy. The percentage range used to classify a result as low mosaic can vary between laboratories.

How the mosaic level is estimated from a small biopsy sample

The percentage on your report comes from a biopsy of around five to ten cells taken from the outer layer of the blastocyst.

The tiny amount of DNA in those cells is copied and analysed together as one sample. For each chromosome, the laboratory measures how much DNA is present.

When the cells contain the expected two copies of a chromosome, the amount of DNA follows a euploid pattern. An extra copy produces more chromosome material. A missing copy produces less.

A mixture produces a measurement between those patterns. The laboratory uses how far the measurement has shifted from the euploid amount to estimate the proportion of cells in the biopsy carrying the extra or missing chromosome finding.

The percentage is an estimate, not a count of individual cells. A result reported as 30% mosaic does not establish that exactly 30% of the embryo is abnormal. It means the pooled DNA from that small biopsy was consistent with the laboratory’s 30% mosaic range.

The biopsy gives useful information about the cells tested. It cannot provide a cell-by-cell map of the whole embryo.

How a low mosaic embryo compares with an available euploid embryo

When a euploid embryo and a low mosaic embryo are both available, the euploid embryo will usually be transferred first.

In a matched study comparing low mosaic and euploid embryo transfers, 41.7% of low mosaic transfers resulted in a clinical pregnancy, compared with 57.7% of euploid transfers. The live birth rates were 38.3% and 51.4%.

That is roughly four live births for every ten low mosaic embryos transferred, compared with five for every ten euploid embryos in this study.

A low mosaic embryo still carries meaningful reproductive potential. The difference is that an available euploid embryo has the more reassuring PGT-A result and the stronger expected outcome, so it is usually given transfer priority.

The low mosaic embryo can remain available if another transfer is needed.

Comparing a low mosaic embryo with your other mosaic embryos

When more than one mosaic embryo is available, the mosaic level can help determine transfer order.

A low mosaic embryo is often prioritised over a high mosaic embryo because the biopsy contained a smaller proportion of abnormal chromosome material.

In one study, 44.6% of low mosaic transfers resulted in a live birth, compared with 36% of high mosaic transfers. The difference was not statistically significant, but the miscarriage rates were 5.1% and 30.7% respectively.

The high mosaic group was small, so the size of the difference remains uncertain. Even so, the findings help explain why a low mosaic embryo may be placed ahead of a high mosaic embryo when both are available.

When two embryos are both low mosaic, a small difference between their reported percentages should not carry the whole decision. The chromosome finding and embryo grade still contribute to the comparison.

Why the chromosome finding still matters

Two low mosaic embryos with the same reported percentage may carry very different chromosome findings.

One may involve part of a single chromosome, known as a segmental finding. Another may involve an entire chromosome. A third may involve several chromosomes.

In a study of 1,000 mosaic embryo transfers, 43.1% of segmental mosaic transfers resulted in an ongoing pregnancy or birth. The rate was 34.8% when one whole chromosome was involved, 34.4% when two chromosomes were involved and 20.8% for complex findings involving three or more chromosomes.

Those figures show why “low mosaic” cannot carry the whole comparison. How much of the chromosome is affected and how many chromosomes are involved can change transfer priority.

The chromosome number itself does not currently provide a reliable ranking for transfer success. It still matters because some chromosome findings can continue into pregnancy, and the chromosome named on the report affects the genetic counselling and prenatal diagnostic testing discussed if pregnancy follows.

A low mosaic percentage is one part of the result. The full finding tells you what kind of mosaicism was detected and what questions need to be answered before that embryo is placed ahead of another.

What embryo grading contributes to the comparison

Your embryo grade becomes most useful when two embryos have similar PGT-A findings.

The grade records how the blastocyst developed before it was frozen. The number describes how far it had expanded. The first letter describes the group of cells that develops into the baby, and the second describes the outer cells that help form the placenta.

A stronger grade is associated with a greater chance of continued development after transfer. In one study, 57.1% of good-grade mosaic embryos resulted in a live birth, compared with 38.1% of fair or poor-grade mosaic embryos.

The study was small, so the size of that difference remains uncertain. It still shows why grading contributes useful information when the mosaic level and chromosome findings are otherwise similar.

A well-graded low mosaic embryo may therefore be prioritised over a more poorly graded mosaic embryo with a comparable PGT-A result. The grade adds to the chromosome information. It does not replace it.

How maternal age at egg collection affects the chance of other euploid embryos

Maternal age at egg collection is one factor used to estimate how likely the other embryos from that retrieval are to be euploid.

Recent research shows that the follicular environment in which the egg matured also affects whether its chromosomes separate correctly. Maternal age therefore contributes to the estimate, but it does not explain the chromosome result on its own.

For embryos already created, the relevant age is maternal age at egg collection, not your current age.

How current age, low AMH and previous ovarian response affect another retrieval

If you are deciding between transferring your low mosaic embryo and attempting another egg collection, the relevant question is what another retrieval is realistically likely to produce now.

Your current maternal age contributes to the chance that any new embryos will be euploid. AMH helps estimate how many eggs your ovaries may produce in response to stimulation. It does not measure the quality or chromosome status of those eggs.

Your previous IVF cycle shows how your ovaries and embryos actually responded. The number of mature eggs collected, how many fertilised, how many reached blastocyst and the PGT-A results provide more individual context than AMH alone.

A previous cycle that produced several blastocysts may support considering another retrieval, even with low AMH. A low response followed by few or no blastocysts may mean another cycle is less likely to change the embryos available.

These factors establish whether another egg collection offers a realistic alternative to transferring the low mosaic embryo you already have.

When the low mosaic embryo may be your strongest remaining option

A low mosaic embryo may become your strongest remaining option when no euploid embryos are available and another egg collection is unlikely to produce a better embryo.

This is more likely when previous retrievals produced few mature eggs or blastocysts, current AMH suggests a limited response and maternal age reduces the prospect of creating a euploid embryo in another cycle.

The decision is then between the embryo already available and the time, cost and physical demands of another retrieval with an uncertain outcome.

The full PGT-A finding and embryo grade still matter. A low mosaic embryo with a more favourable chromosome finding and stronger grade may offer a more realistic route to transfer than another mosaic embryo or another retrieval with a low expected yield.

Calling it your strongest remaining option does not remove uncertainty. It means that, after the alternatives are compared honestly, this embryo may offer the clearest remaining path to pregnancy.

You are right. That sentence repeats the same empty contrast you had already rejected: it states what sibling plans do not affect instead of explaining what they change in the decision.

How future sibling plans affect transfer priority

The number of children you hope to have can affect whether transfer or another egg collection comes first.

If one child is your goal, the decision can focus on the strongest embryo already available.

If you hope for more than one child, another retrieval before transfer may preserve the chance to create embryos for a future sibling. A successful transfer would delay any further egg collection until after pregnancy and recovery, when maternal age may reduce the expected number of euploid embryos created.

This is why a low mosaic embryo may be ready for transfer but still follow another egg collection in the treatment plan.

The decision is not only which embryo offers the strongest option now. It is whether using that embryo now leaves enough opportunity to build the family you hope for.

Questions to ask before choosing which embryo to transfer

Before choosing transfer order, ask your clinic to compare the embryos and treatment options available to you as a whole.

• Do I have a euploid embryo that would usually be transferred first?
• How does this low mosaic embryo compare with my other mosaic embryos?
• Is the finding segmental or does it involve a whole chromosome?
• How many chromosomes are involved, and which chromosome has been identified?
• How does the embryo grade affect its place in the transfer order?
• What did my previous retrieval show about my likely response to another egg collection?
• Given my current maternal age and AMH, is another retrieval likely to change the options available?
• Would delaying transfer for another retrieval better support our plans for future siblings?
• Does the clinic recommend genetic counselling before transfer?
• If the transfer leads to pregnancy, which prenatal diagnostic tests would be discussed?

You should leave that conversation knowing which embryo your clinic recommends transferring first, why it has been prioritised and whether another egg collection should happen before transfer.

The PGT-A result, chromosome finding and embryo grade are already fixed. Once transfer is going ahead, the next concern is whether implantation can progress successfully.

That is where your preparation still matters.

Your Opportunity to Support Implantation

Choosing to transfer a low mosaic embryo can bring relief that there is a way forward and fear that this embryo may have a lower chance of success than a euploid embryo.

When it may be your strongest remaining option, you want to know what can still be done to support implantation

Implantation has 5 distinct phases and each has to complete successfully for pregnancy to continue.

During those phases, the embryo must attach and embed, cells divide and take on specialised roles, early blood vessels develop, the immune system adapts and the first placental structures begin to form.

This work increases the demand for energy, amino acids, essential fats, vitamins and minerals. These nutrients provide the raw materials used for cell division, gene regulation, immune adaptation and early vascular development.

Providing those nutrients consistently during the implantation window is one part of the process still within your control.

The professionally created Now Baby FET Implantation Support Meal Plan turns those nutritional requirements into a complete structure for the two-week wait. Every meal is measured and balanced around the demands of the five-stage implantation process, so you are not left trying to translate scientific research into day to day meals,  while waiting for your beta test..

Get the FET Implantation Support Meal Plan

When you have one or more mosaic embryos, you may have a decision about what happens next.

You may be deciding whether to transfer one of them, which embryo should be transferred first, or whether to consider another egg collection before using the embryos already in storage.

Your mosaic result is one part of that decision. It needs to be considered alongside the embryos you already have and the options still open to you.

You may also have a euploid embryo available. Or a mosaic embryo may be your only remaining embryo.

When several mosaic embryos are available, their individual findings may affect which one is considered first.

Another egg collection may still be possible. But your current age, AMH, previous ovarian response and willingness to go through another retrieval will shape whether it is a realistic option.

Your age when the eggs were collected and your hopes for a future sibling also belong in the decision.

That is the context to take into the discussion with your clinic and genetic counsellor.

What a mosaic embryo result means

Your PGT-A report describes the chromosome pattern detected in the cells tested from your embryo.

Most human cells carry two copies of each chromosome. During PGT-A, the laboratory measures the amount of DNA associated with each chromosome and compares it with the amount expected when both copies are present.

A euploid result falls within that expected range. An aneuploid result shows a clearer gain or loss of chromosome material. A mosaic result is reported when the DNA signal falls between those two ranges.

Your result may involve a whole chromosome or part of a chromosome, known as a segmental finding. It may also be reported as low-level or high-level mosaicism according to where the DNA signal falls within the laboratory’s reporting range.

The word mosaic therefore describes the chromosome pattern detected during PGT-A. The chromosome involved, the type of finding and the reported mosaic level provide the detail needed to understand your individual result.

A mosaic result therefore gives you the chromosome finding recorded by the laboratory. Before it can guide a transfer decision, you need to understand how closely the cells tested can represent the embryo they came from.

Why the biopsy cannot describe every cell in the embryo

Your PGT-A result comes from a small group of cells removed from one area of the blastocyst.

Those cells are taken from the trophectoderm, the outer layer that later contributes to the placenta. The inner cell mass, which develops into the fetus, remains inside the embryo and is not biopsied.

The laboratory analyses the combined DNA from the cells in that sample. It does not test cells from every part of the embryo.

This matters more when a mosaic result is reported because different chromosome patterns may not be spread evenly. The sampled area may contain a different mixture of cells from another area of the trophectoderm or from the inner cell mass.

The biopsy therefore shows what was detected in the cells tested. It cannot provide a cell-by-cell map of the whole embryo.

Once that limitation is clear, the next step is to consider where this embryo sits among the embryos still available to you.

Where the mosaic embryo sits among your remaining embryos

Your mosaic embryo needs to be considered alongside every other embryo you still have in storage.

You may have an embryo reported as euploid, other mosaic embryos, embryos that were not tested, or no other embryo available for transfer.

The same mosaic result can therefore lead to a different discussion depending on what remains. When it is your only embryo, it may represent a possible route to transfer. When other embryos are available, its place has to be considered in relation to those options.

This is why your clinic and genetic counsellor need to review the full embryo list rather than one report in isolation.

The first distinction is whether a euploid embryo is also available.

How an available euploid embryo changes the transfer order

When a euploid embryo is available, many clinics will place it ahead of a mosaic embryo in the transfer order.

The euploid result shows that the cells tested had the expected amount of chromosome material. That gives the clinic an embryo with less uncertainty attached to the PGT-A finding and is why professional guidance commonly supports transferring a euploid embryo first.

Your mosaic embryo can remain available for a later transfer. Its place in the order becomes relevant if the euploid embryo does not lead to pregnancy or when another transfer is needed for future family plans.

Some clinics may also consider embryo grading alongside the PGT-A result, particularly when a low-range mosaic embryo is being compared with a euploid embryo. The clinic’s own policy and the details of both embryos therefore still matter.

When no euploid embryo is available, the decision moves to how the mosaic embryos compare with each other.

When several mosaic embryos need to be compared

When you have several mosaic embryos, your clinic needs to decide which one should be transferred first.

Each embryo has its own PGT-A result. The reported mosaic level, whether the finding involves a whole chromosome or part of one, the chromosome affected and the embryo grading may all be considered together.

These findings can place embryos differently in the transfer order, even when they are all described as mosaic.

That comparison starts with the chromosome finding and the reported mosaic level, because both can affect which embryo is considered first.

Why the chromosome finding and mosaic level both matter

When your clinic compares your mosaic embryos, it will look at two parts of each result: the chromosome finding and the reported mosaic level.

The chromosome finding shows whether the result involves a whole chromosome or part of one, and whether one or several chromosomes are involved. Segmental mosaic results have sometimes been associated with better transfer outcomes than whole-chromosome mosaic results. Embryos with several chromosomes involved may also be considered differently from those with a single finding.

The specific chromosome can also affect what your genetic counsellor needs to discuss with you and which prenatal testing options may be relevant if the transfer leads to pregnancy.

The mosaic level describes where the DNA signal from the biopsy sits between the euploid and aneuploid ranges. A lower-level result sits closer to the euploid range. A higher-level result sits closer to the aneuploid range.

Some studies have associated higher reported mosaic levels with a lower chance of implantation or ongoing pregnancy. The level is still an estimate from the cells biopsied rather than a count of abnormal cells across the whole embryo, and laboratory reporting thresholds can differ.

Both details therefore help your clinic explain why one mosaic embryo may be considered before another. The embryos in storage were also created from eggs collected at a particular age, and that age shapes the wider chromosome picture.

Why the chromosome finding and mosaic level both matter

When your clinic compares your mosaic embryos, it will look at two parts of each result: the chromosome finding and the reported mosaic level.

The chromosome finding shows whether the result involves a whole chromosome or part of one, and whether one or several chromosomes are involved. Segmental mosaic results have sometimes been associated with better transfer outcomes than whole-chromosome mosaic results. Embryos with several chromosomes involved may also be considered differently from those with a single finding.

The specific chromosome can also affect what your genetic counsellor needs to discuss with you and which prenatal testing options may be relevant if the transfer leads to pregnancy.

The mosaic level describes where the DNA signal from the biopsy sits between the euploid and aneuploid ranges. A lower-level result sits closer to the euploid range. A higher-level result sits closer to the aneuploid range.

Some studies have associated higher reported mosaic levels with a lower chance of implantation or ongoing pregnancy. The reported mosaic level is inferred from the DNA signal in the biopsied cells. It is not a count of abnormal cells across the whole embryo. Laboratory reporting thresholds can also differ.

Both details therefore help your clinic explain why one mosaic embryo may be considered before another. The embryos in storage were also created from eggs collected at a particular age, and that age shapes the wider chromosome picture.

When another egg collection is not a simple alternative

When a mosaic embryo is available, another egg collection may appear to offer a clearer option: create a euploid embryo first and return to the mosaic embryo only if it is still needed.

But another retrieval offers the possibility of a euploid embryo, not the certainty of one.

The embryos already in storage reflect your age when those eggs were collected. A new retrieval would depend on your current age, AMH and previous ovarian response. Age affects the chance that the cycle produces a euploid blastocyst. Low AMH or a low previous response may also reduce the number of eggs available to create embryos.

In a 2024 study of 2,462 IVF–PGT-A cycles using women’s own eggs, the proportion ending without a euploid blastocyst was 22% at age 35, 58% at 40 and 92% at 44. These figures cannot predict the outcome of your cycle, but they show why another egg collection is not a guaranteed alternative to the mosaic embryo already available.

Another retrieval may create a different transfer option. It may also end without a euploid embryo, leaving the mosaic embryo already available as the option still in front of you

The decision is therefore between transferring the mosaic embryo you have and delaying transfer for the uncertain chance of creating another option.

How many children you hope to have can change which of those choices carries more weight.

How future family plans influence which embryo is transferred first

The transfer order may affect more than your next pregnancy. It can also shape the embryos available if you hope to return for a sibling.

When one child is the goal, your clinic may focus on which embryo should be prioritised for the next transfer.

When you hope to have more than one child, the order can carry more weight. Transferring the only euploid embryo first may leave a mosaic embryo as the remaining option for a future pregnancy. Delaying transfer for another egg collection may preserve the embryos already in storage, but it also depends on what another retrieval could realistically produce now.

Your family plans therefore belong in the transfer discussion from the beginning.

Your clinic and genetic counsellor need to know whether the decision is about one pregnancy or the embryos you may need to build the family you are planning.

Nutrition support once the transfer decision is made

Despite PGT-A testing, not all transfers are successful.

PGT-A helps guide the embryo decision. Once transfer takes place, pregnancy depends on the biological work that follows.

Implantation has 5 distinct phases and each has to complete successfully for pregnancy to continue.

During those stages, cells divide rapidly, genes are regulated, blood vessels begin to develop, the immune system adapts and the earliest placental structures begin to form.

Each of these processes depends on a consistent supply of energy, amino acids, essential fats, vitamins and minerals. Food is how those nutritional raw materials are supplied during the days between transfer and beta.

Your clinic will prepare you meticulously for transfer. You can bring that same level of preparation to meeting the nutritional demands of your embryo at this critical phase.

The Now Baby professionally designed  FET Implantation Support Meal Plan takes the guesswork out of this window. It translates the science of the 5-stage implantation process into a structured 14-day food protocol, with every meal designed around the nutritional and metabolic demands between transfer and  your beta test.

Get the FET Implantation Support Meal Plan

Realising you have missed a progesterone dose after FET can make one mistake feel bigger than the entire protocol you followed to reach transfer.

Before beta, the fear is that you have disrupted implantation. After a positive beta, the fear is for the pregnancy your result has confirmed.

The missed dose is the same, but the question it creates is different.

Before Beta, Progesterone Is Supporting Implantation

Before beta, progesterone is keeping your uterine lining in the receptive state your embryo needs as it attaches and embeds. It drives decidualisation, the process that changes lining cells into specialised tissue around the implantation site. This tissue helps regulate how your embryo moves into the lining, local immune activity and the remodelling of blood vessels around it.

In a medicated FET, the progesterone you take is providing this support because the cycle is usually created without ovulation and without a corpus luteum producing progesterone. In a natural or modified natural FET, your corpus luteum also produces progesterone, while prescribed progesterone may be added as luteal support.

That difference is part of what your clinic needs to assess when a dose is missed. The type of FET, the progesterone product and route, when the dose was due and how long the gap has been all shape the advice you need next.

What to Do If You Miss Progesterone Before Beta

When you realise a progesterone dose has been missed, contact the clinic managing your FET with the exact timeline. Tell them the name and strength of your progesterone, how it is administered, when the dose was due, when you noticed and what doses you have taken since.

“Missed a dose” does not describe the size of the gap or how it fits into your prescribed schedule. Those details allow your clinic to assess what happened and tell you how to continue.

When the clinic is closed, use the out-of-hours contact or the missed-dose guidance supplied with your treatment protocol. Advice given to another IVF patient cannot answer this safely because her medication, timing and FET protocol may not match yours. Progesterone support is prescribed through different routes and regimens, so the next step must come from the team managing your cycle.

Can One Missed Progesterone Dose Affect Implantation?

One missed dose may reduce the progesterone exposure planned by your clinic for part of the implantation window. How much that matters depends on the length of the gap, how progesterone is administered and whether your FET cycle also has progesterone production from a corpus luteum. Your clinic assesses those details against the full pattern of doses already taken. Progesterone remains critical for endometrial support and implantation, but the significance of one missed dose has to be interpreted within your complete protocol.

Progesterone provides the hormonal support only. Implantation has 5 distinct phases and each has to complete successfully for pregnancy to continue.

Each stage has its own nutritional and physiological demands. Cells need energy to divide, amino acids to build new tissue, essential fats to form cell membranes and specific micronutrients for blood-vessel development, gene regulation and immune adaptation. Metabolic stability affects how consistently those resources are available while this work continues.Hormones cannot complete these five processes.

This is not a task that supplements can deliver either. These processes depend on a consistent supply of targeted nutrients together with the metabolic stability needed to use them.

Embryo implantation beyond hormone support

The implantation window depends on more than progesterone. There are multiple factors unfolding in a short window, the outcome of which decides whether your pregnancy progresses or not. Your clinic is not leaving anything to chance, and you shouldn’t either. The role of specific nutrients is critical to your success, and you have an opportunity to support this intentionally.

At Now Baby, we have taken the guesswork out for you and created a professionally curated FET implantation support meal plan. Each day of the two week wait before your beta test matters and what you eat during that phase matters too.

Get the FET Implantation Support Meal Plan

After a Positive Beta, Progesterone Is Supporting Early Pregnancy

After a positive beta, progesterone continues to maintain your uterine lining while the pregnancy develops and the placenta begins to form.

In a natural or modified natural FET, hCG from the pregnancy signals the corpus luteum to keep producing progesterone. In a fully medicated FET, ovulation did not create a corpus luteum, so prescribed progesterone remains the source of that hormonal support.

The placenta gradually takes over progesterone production during the first trimester. The stop date in your protocol is set around this hormonal handover.

A missed dose after beta therefore has to be assessed within the source of progesterone in your cycle and how far the pregnancy has progressed.

What to Do If You Miss Progesterone After a Positive Beta

After a positive beta, contact the clinic managing your progesterone support with the exact medication timeline. Include the progesterone name and strength, how it is administered, when the dose was due, when you realised it had been missed and every dose taken since.

The clinic also needs to know how far the pregnancy has progressed and whether your FET was natural, modified natural or fully medicated. Those details show whether progesterone is coming from a corpus luteum, prescribed medication or a combination of both, and allow the missed dose to be assessed within the support available at that stage.

When your fertility clinic is closed, use its out-of-hours contact or the missed-dose guidance supplied with your protocol. If your care has already transferred to another maternity service, contact the team now responsible for your early pregnancy. The next step needs to come from a clinician who knows your FET protocol and current progesterone prescription.

Can One Missed Progesterone Dose Cause Miscarriage?

After a positive beta, missing progesterone can feel as though one mistake has put the pregnancy you have worked so hard to reach at risk. The significance of that missed dose depends on the progesterone support available across your full protocol and how far the pregnancy has progressed.

Research has linked lower progesterone exposure in programmed FET cycles with poorer pregnancy outcomes. Those studies measure progesterone levels or compare complete support regimens. They do not isolate one missed dose after a positive beta, so they cannot calculate the miscarriage risk created by that single event.

The length of the gap, how progesterone is administered and whether progesterone is also being produced by a corpus luteum all shape the support available during that time. Your clinic will assess those details alongside the follow-up used to monitor your pregnancy.

One missed dose is not evidence that you caused harm.

The Outcome of Your Pregnancy Relies on More Than a Single Progesterone Dose

Your pregnancy is supported by the full pattern of progesterone exposure across your protocol, the source of progesterone available in your cycle and the development already underway. A missed dose is one part of that wider picture.

Giving your clinic the exact timeline allows them to assess the gap properly and guide what happens next. You do not have to carry the meaning of that missed dose alone.

One moment in a carefully managed protocol does not define the outcome of your pregnancy.

A medicated frozen embryo transfer cycle uses prescribed hormones to prepare the uterine lining and control the timing of embryo transfer.

Oestrogen and progesterone are given in sequence because each hormone has a different role in preparing the lining. Oestrogen comes first. Progesterone begins later, once the clinic decides the cycle is ready to move forward.

During the oestrogen stage, scans and sometimes blood tests help the clinic assess your response and decide what happens next.

What oestrogen does before frozen embryo transfer

The first job in a medicated FET cycle is to develop your uterine lining. Oestrogen provides the signal for that growth.

Under its influence, the endometrium rebuilds and becomes thicker as its cells multiply. Oestrogen also increases progesterone receptors within the tissue, preparing the lining to respond to the next hormone in the protocol.

This first stage needs to be established before the cycle can move on.

When oestrogen starts in a medicated FET cycle

In many medicated FET cycles, oestrogen starts on day 2 or day 3 of your bleed. Beginning early allows the clinic to take over the hormone timetable before ovulation would ordinarily determine what happens next.

A baseline scan may be arranged before the first dose. At this stage, the clinic is looking for a thin uterine lining and ovaries without a developing follicle or a cyst producing hormones. Blood tests may also be used to check that oestrogen and progesterone are low enough for the planned cycle to begin.

Day 2 or day 3 is not the starting point in every protocol. Medication may have been given during the previous cycle to suppress your natural hormone activity or help schedule treatment. Oestrogen then begins once that suppression has been confirmed, rather than according to the first days of a spontaneous cycle.

Irregular or absent periods can also change how the start is organised. The clinic may induce a withdrawal bleed or use scan and blood-test results to identify the point at which oestrogen can begin.

Oestrogen is commonly taken for around 10 to 14 days before the first lining assessment, although this is not a fixed countdown to transfer. The oestrogen stage can often be extended when more time is needed or when the clinic needs to adjust the treatment schedule.

That flexibility changes once progesterone begins. From that point, the number of hours or days of progesterone exposure must be matched much more closely to the developmental stage of the embryo being transferred.

How your uterine lining is monitored

After around 10 to 14 days of oestrogen, many clinics arrange a transvaginal ultrasound to see how your uterine lining has responded.

The sonographer measures the endometrium in millimetres and may also assess its appearance. Before progesterone begins, the lining may show a three-layered, or trilaminar, pattern on ultrasound.

The ovaries are checked at the same appointment. A growing dominant follicle could indicate that your own cycle is becoming active, which may affect the hormone timetable. The scan can also identify fluid within the uterine cavity or another finding that needs to be reviewed before the cycle moves forward.

Blood-test monitoring varies between clinics. Oestradiol may be measured to assess hormone exposure, while progesterone may be checked to confirm that it remains low before progesterone medication is started. An unexpected rise in progesterone can change the planned timing because the lining may already have begun moving into its next stage.

The scan and blood-test results determine whether the clinic can set your progesterone start date or whether oestrogen should continue before the lining is assessed again. Some cycles move forward after one monitoring appointment. Others need another scan or a change to the protocol first.

Why lining thickness is only one part of readiness

Lining thickness gives the clinic a clear, measurable sign that the endometrium has responded to oestrogen. A very thin lining is associated with lower pregnancy and live birth rates across groups of FET patients, which is why clinics pay close attention to the measurement.

Many clinics use a figure such as 7 mm or 8 mm as a practical guide when deciding whether the cycle is ready to move forward. But the endometrium does not change from unready to ready at one exact number. The measurement shows how the lining has developed and forms one part of the clinic’s overall assessment.

Ultrasound can measure the depth and appearance of the tissue. It cannot show everything happening within it, including how the endometrial cells will respond once progesterone begins or whether the lining will become receptive at the expected time.

Lining thickness matters. It is most useful when interpreted alongside the lining pattern, hormone results, the timing of the protocol and your wider clinical picture.

Oestrogen tablets, patches and other routes

Oestrogen can be given as tablets, patches, gel or, in some protocols, vaginal medication. Each route is being used for the same purpose: to provide enough oestrogen exposure for the uterine lining to develop before progesterone begins.

Tablets are commonly prescribed because the dose is easy to adjust. They may be taken once or several times each day as the amount of oestrogen is increased through the cycle. Oral oestrogen passes through the digestive system and liver before reaching the bloodstream, which can affect how much medication is available to the tissues.

Patches release oestrogen through the skin over a set number of days. This provides a more continuous delivery and avoids the first passage through the liver. The practical drawbacks are usually local: patches can loosen or irritate the skin, particularly when several need to be worn at the same time.

Oestrogen gel is also absorbed through the skin. It needs to be applied to the recommended area and allowed to dry before the skin is covered or comes into contact with another person.

Some clinics prescribe oestrogen vaginally, either as the main route or alongside tablets or patches. Vaginal administration produces greater exposure within the uterine tissue, although it may also cause discharge and can make blood oestradiol results harder to interpret in the same way as oral or transdermal dosing.

No single route has been shown to be the best choice for every medicated FET cycle. Your clinic may base the prescription on its usual protocol, your medical history, how you tolerate the medication and how your lining responds.

What happens if your lining is slow to develop

The first lining scan gives your clinic a point from which to adjust the protocol. When the endometrium has developed more slowly than expected, oestrogen can usually continue for several more days before another scan is arranged.

The dose may be increased, or the route changed or combined to alter how the medication is absorbed. Where blood tests form part of the protocol, the oestradiol result may also help the clinic assess whether the current medication exposure is adequate.

A slower response at the first scan does not show that the lining has reached its final thickness. Some endometria need longer exposure to oestrogen, and this stage of a medicated FET cycle usually allows room for that extension.

When the lining remains thin despite additional time and changes to the medication, the clinic may look beyond the current dose. Previous scan measurements and treatment cycles can help show whether this is a repeated pattern.

The next decision is individual. The clinic may proceed using the best measurement reached or postpone the transfer and plan a different approach for another cycle.

What changes when progesterone begins

The first dose of progesterone marks a clear change in the FET cycle. Until this point, the uterine lining has been developing under oestrogen. Progesterone now changes the lining from tissue that is still growing into tissue preparing to receive an embryo.

The endometrial cells begin producing and releasing substances involved in the earliest contact between the embryo and the lining. Progesterone also changes the structure, blood supply and signalling activity within the endometrium as it moves towards its receptive phase.

The timetable becomes much more precise from this point. Your clinic counts the length of progesterone exposure before transfer so that the stage reached by the lining is matched to the developmental stage of your embryo. A Day 3 embryo and a Day 5 blastocyst therefore follow different progesterone schedules.

Oestrogen usually continues after progesterone begins, but its role has changed. It is no longer being used primarily to develop the lining. In a medicated FET cycle, ovulation does not occur and no corpus luteum forms to produce the oestrogen that would normally remain present during the luteal phase. The medication maintains that oestrogen exposure while progesterone controls the next changes within the endometrium.

Progesterone timing is measured from the first dose. Taking it earlier, later or differently from the prescribed schedule can change the number of hours the lining has been exposed before transfer, which is why your clinic gives an exact time for the medication to begin.

The lining is prepared. The five stages of implantation come next.

Your clinic has managed the hormonal support to bring you here. The implantation process that is about to unfold has five distinct stages: uterine lining receptivity, early blood supply, gene expression and cellular differentiation, placental formation and immune modulation.

Each stage has its own nutritional and physiological demands. Cells need energy to divide, amino acids to build new tissue, essential fats to form cell membranes and specific micronutrients for blood-vessel development, gene regulation and immune adaptation. Metabolic stability affects how consistently those resources are available while this work continues.

Hormones cannot complete these five processes.

This is not a task that supplements can deliver either. These processes depend on a consistent supply of targeted nutrients together with the metabolic stability needed to use them.

Embryo implantation beyond hormone support

The implantation window depends on more than oestrogen and progesterone. There are multiple factors unfolding in a short window, the outcome of which decides whether your pregnancy progresses or not. Your clinic is not leaving anything to chance, and you shouldn’t either. The role of specific nutrients is critical to your success, and you have an opportunity to support this intentionally.

At Now Baby, we have taken the guesswork out for you and created a professionally curated FET implantation support meal plan. Each day of the two week wait before your beta test matters and what you eat during that phase matters too.

Get the FET Implantation Support Meal Plan

By the time embryo transfer is being planned, your body is already shaping the conditions your embryo will meet.

Transfer timing determines when your embryo is placed into your uterus.
Your body determines what happens next.

It is not simply a choice between fresh or frozen.
The important factor is what state your body is in when your embryo begins connecting with you.

How fresh and frozen transfer create different implantation starting points

Fresh transfer places the embryo into your uterus during the same cycle as egg retrieval, while your body is still recovering from stimulation.

Your hormone levels are still elevated.
Your body is still settling after the procedure.
Blood flow and immune activity have not fully settled at that point.

Your embryo begins connecting to you within that environment.

This means implantation is starting while your body is still adjusting.

Frozen transfer separates embryo transfer from the stimulation cycle, giving your body time to recover before implantation begins.

Hormone levels have time to settle.
Your uterus can be prepared more precisely.
Your body is in a more stable state at the point your embryo is transferred.

This creates a more controlled starting point for implantation.

How your body’s state affects implantation

Implantation is not automatic once an embryo is transferred.

It begins in the days that follow, as your embryo starts to attach and take hold within your uterus.

This is where the process that leads to your positive pregnancy test begins.

If your body is still fluctuating after stimulation, the process of implantation begins while your system is not yet fully settled.

If your body has stabilised, it begins within a more prepared environment.

This is where implantation either begins to build or struggles to establish.

You have already done everything required to reach this point.

What happens next is how implantation builds over the days that follow.

This period is often described as the two-week wait.

But it is not a passive phase.

It is when implantation is actively building towards your positive pregnancy test.

Implantation builds across 5 distinct phases within your uterus over the days that follow transfer, from initial attachment through early blood supply, placenta development and immune adaptation. Each phase must complete successfully for pregnancy to continue.

The distinct phases place different nutritional demands on your body as implantation continues to establish.

Implantation is supported by the right nutrients at the right time.

Get The Implantation Support Plan Now

Progesterone support will form part of your transfer protocol.

It prepares your uterus so implantation can begin.

Once transfer has taken place, implantation continues over the following days as early pregnancy starts to establish.

Your body is actively responding throughout this time.

Progesterone remains part of that process.

Implantation continues beyond it.

When fresh transfer remains appropriate

Fresh transfer can work well when your body has responded in a controlled way to stimulation and has settled quickly after retrieval.

Hormone levels are not excessively elevated.
Recovery is smooth.
Your body is already in a stable state when transfer takes place.

In this situation, implantation can begin in an environment that is already prepared.

When frozen transfer becomes the better option

Frozen transfer is often used when your body needs more time to recover after stimulation.

Hormone levels may be higher.
Recovery may take longer.
Your system may not yet be fully settled at the time your embryo would otherwise be transferred.

Delaying transfer allows your body to return to a more stable state before implantation begins.

Whether your transfer is fresh or frozen, this is the point where everything comes together.

You have already done everything required to reach this stage.

What matters now is how implantation will build over the days that follow.

Your embryo will begin to take hold within your uterus.

This is where that process will build, step by step, towards your positive pregnancy test.

And how consistently your body is supported during that time will influence how successfully that process builds.

Two out of three untested embryo transfers do not lead to a live birth. Implantation failure is not a rare outcome at the edges of IVF. It is part of the reality of embryo transfer for most couples.

When your pregnancy test is negative, the result is clear. The reason it happened is not.

You reached transfer because an embryo had developed far enough to be placed into your uterus. From that point, pregnancy depended on several biological events unfolding in sequence between the embryo and the uterine lining.

A failed transfer tells you that pregnancy did not establish. It cannot show where that sequence stopped, why it stopped or whether the embryo was the only factor involved.

Understanding that distinction changes the question from “Why did my embryo fail?” to “What may have prevented implantation from continuing?”

What Does Implantation Failure After Embryo Transfer Mean?

Implantation failure means the transfer did not progress to an established pregnancy. The embryo was placed into the uterus, but the biological sequence needed to produce a detectable pregnancy did not continue far enough for hCG to rise.

Implantation is often described as the embryo attaching to the uterine lining. Attachment is only one stage. The embryo must make contact with the lining, begin to embed, communicate with surrounding cells and start the earliest stages of placental development.

A negative pregnancy test cannot show where that sequence stopped. It confirms the outcome, but not the point at which implantation was interrupted.

This is why implantation failure describes what happened rather than explaining why it happened. After one unsuccessful transfer, it does not prove there is a specific problem with the embryo, the egg or sperm that created it, the uterine lining or your ability to carry a pregnancy.

Why Can IVF Fail After Embryo Transfer?

After transfer, implantation depends on three variables: the embryo, the uterine lining and the maternal environment supporting both.

The embryo must continue developing after transfer. By then, its developmental capacity has been shaped by the egg and sperm that created it, the genetic material it carries and how its cells have divided since fertilisation.

Embryo grading describes how the embryo looked and developed in the laboratory. PGT-A checks chromosome numbers in a small sample of cells. Even a well-graded embryo reported as euploid can fail to implant because neither assessment can predict everything that happens after transfer.

The uterine lining must become receptive at the right time. Its response to progesterone helps determine when the embryo can attach and begin embedding.

The maternal environment must then support the developing relationship between the embryo and lining. Cellular energy production, immune regulation, nutrient availability and early blood-vessel development all form part of the conditions in which implantation continues.

A failed transfer may involve one variable or several overlapping factors. The negative pregnancy test confirms that pregnancy did not establish. It cannot identify which part of the process prevented it from continuing.

Before the cycle is reviewed, implantation failure needs to be confirmed by the beta hCG result. A negative beta means the transfer did not establish a detectable pregnancy. If hCG rose and then fell, implantation began but did not continue. That is a biochemical pregnancy, not implantation failure.

What Should Be Reviewed After a Failed Embryo Transfer?

Once implantation failure is confirmed by a negative beta hCG result, the cycle should be reviewed as a whole.

Your clinic may revisit the embryo, the lining preparation, progesterone timing and the transfer itself. That review can identify whether anything within the treatment cycle needs to change.

It cannot always explain why implantation stopped.

The next transfer still depends on the embryo, the lining and the maternal environment supporting both. That is where preparation before another transfer remains relevant.

Can Implantation Failure Be Prevented?

A failed transfer does not reveal one cause that can simply be removed before the next attempt.

Some factors are already fixed. The embryo has been created, the egg and sperm have contributed to its development and that transfer has already taken place.

Other factors remain open to review or change. These may include the uterine cavity, lining preparation, progesterone exposure, transfer timing and which embryo is selected next.

Depending on your history, your clinic may discuss:

• PGT-A
• sperm DNA damage testing
• endometrial receptivity testing, including ERA
• immunological testing
• endometrial or reproductive-tract microbiome testing

Each test examines a specific part of the implantation picture. None can assess the full maternal environment in which implantation must continue.

Implantation has 5 distinct phases and each has to complete successfully for pregnancy to continue.

During the days between embryo transfer and the beta hCG result, biological activity increases rapidly. The embryo continues dividing while its cells begin taking on different roles in the developing embryo and the structures that will support the pregnancy.

Each new cell must produce energy, copy DNA, build proteins and cell membranes and respond to signals from surrounding cells. As cell division and differentiation accelerate, the demand for energy and nutrients rises with them.

Amino acids are used to build proteins and new tissue. Fatty acids contribute to cell membranes and cellular signalling. Vitamins and minerals are involved in DNA synthesis, methylation, antioxidant defence, immune adaptation and early vascular development.

Metabolic stability influences how energy is supplied and used during this period. The nutritional demand created by this level of cellular activity extends beyond a supplement routine.

The days between transfer and beta are a period of increased nutritional demand while implantation and early development are underway.

Get the Implantation Support Meal Plan

By the time you reach embryo transfer, the focus shifts from fertilisation outcomes to the moment your embryo is placed into your uterus. Transfer timing now influences how implantation begins and how early pregnancy stabilises in your body.

How embryo development differs between day 3 and day 5

At day 3, your embryo is at the cleavage stage. Cells are dividing, but implantation structures have not yet formed.

By day 5, your embryo has developed into a blastocyst. Fluid expansion has occurred. The inner cell mass and trophectoderm are now distinct. Early developmental direction toward fetal tissue and placenta is already established.

This stage difference affects how prepared your embryo is to initiate implantation signalling after transfer.

How transfer timing shapes the start of implantation

When a day-3 embryo is transferred, development must continue within your uterus before implantation dialogue can begin. Your body supports further cellular organisation, blastocyst formation and metabolic activation during the first post-transfer days.

With a day-5 blastocyst transfer, these early developmental steps have already occurred. Implantation signalling may begin sooner because structural readiness has been reached.

This difference changes how rapidly biological demand increases across the implantation window and how precisely physiological stability must be maintained.

Embryo implantation has 5 distinct phases and each must complete successfully for pregnancy to continue. The two week wait is not a passive, wait and see phase, it is biologically active.

Access the Implantation Meal Plan now

What research shows about success rates

Across many IVF programmes, day-5 blastocyst transfer is associated with higher implantation and clinical pregnancy rates per transfer than day-3 transfer. Embryos that reach blastocyst stage have demonstrated sustained developmental progression, which supports more confident selection at the point of transfer.

However, transfer timing interacts with embryo cohort size, developmental pace and previous treatment history. When embryo numbers are limited or progression is slower, earlier transfer may preserve overall opportunity by allowing the uterine environment to support continued development.

Implantation success therefore reflects biological timing combined with individual cycle dynamics rather than transfer day alone.

Genetic testing considerations

Pre-implantation genetic testing requires access to trophectoderm cells that are present once the embryo reaches blastocyst stage. For this reason, genetic testing is performed on day-5 or later embryos and is not available at the day-3 cleavage stage.

This factor can shape transfer planning when genetic screening forms part of your treatment pathway.

Synchronisation between embryo stage and endometrial receptivity

Implantation depends on precise alignment between embryonic signalling and the receptive phase of your endometrium. Hormonal steadiness, vascular responsiveness and immune tolerance mechanisms all contribute to this timing window.

A day-3 transfer requires sustained physiological stability while development continues internally.

A day-5 transfer requires immediate coordination between an already differentiated embryo and the uterine surface.

In both scenarios, implantation progresses through strengthening attachment signals, adaptive circulation patterns and rising metabolic demand.

As implantation advances after transfer, your embryo deepens biological communication with your body, expands vascular integration and moves toward sustained early pregnancy development.

The HSE calls Ireland’s public fertility service holistic and patient-centred, but what is glaringly missing is the measure of what the patient’s came for.

The HSE Fertility Services Report 2025 counts referrals, appointments, treatment cycles, cycles reaching egg collection, embryo transfers and inseminations.

It describes Ireland’s public fertility service as “holistic” and “patient-centred”. It calls the report comprehensive, the data robust and the service effective.

But it does not measure the outcome the patients came for.

For every couple whose fertility care has ended, there are only two outcomes:

They achieve a pregnancy, or they are discharged without succeeding.

Everything else is the pathway between them.

The service is counted. The patient is not followed.

In 2025, the six regional fertility hubs accepted 5,818 referrals. During the same year, 2,921 new couples attended a consultant appointment, 3,305 attended review appointments and 1,996, just over one third,  were referred onwards for assisted reproduction with an HSE-approved private provider.

These figures show how much work passed through the service.

They do not show how many couples reached either outcome.

The patients referred, assessed and treated during 2025 are not one defined group being followed through the pathway. Some couples counted later in the report entered the service in an earlier year. Others accepted during 2025 were still undergoing investigation or treatment when the year ended.

The HSE says this prevents it from calculating an overall clinical pregnancy rate because fertility pathways can cross calendar years.

But a pathway crossing into another year does not make the patient untrackable.

At the reporting cut-off, the patient is still receiving care, pregnant or discharged without succeeding. Those categories can be carried forward until the pathway ends.

The report does not do that.

The headline success rates begin after the patients most likely to fail have already been removed

The report publishes clinical pregnancy rates of 30% for IVF, 31% for ICSI, 34% for frozen embryo transfer and 11% for IUI.

These percentages are not calculated from everyone who started treatment.

For IVF, ICSI and frozen embryo transfer, the calculation begins with the patients who reached embryo transfer. For IUI, it begins with those who reached insemination.

Patients whose treatment did not reach that stage are excluded from the denominator.

That includes cancelled cycles, cycles that did not reach egg collection, cycles with no embryo available for transfer and IUI cycles that did not proceed to insemination.

These are not patients who stood outside the treatment pathway.

They entered it, underwent treatment and experienced its attrition. Removing them from the denominator makes the published percentage look more successful than the complete treatment journey.

The 30% IVF pregnancy rate becomes 12.4% when the calculation starts where treatment starts

The report records 712 IVF cycles started and 88 clinical pregnancies.

That gives a clinical pregnancy rate of 12.4% per IVF cycle started — not 30%.

The difference is created by the denominator.

The HSE calculates its 30% rate from the 284 IVF cycles that reached fresh embryo transfer. The 428 cycles that started but did not result in a fresh transfer are no longer represented in that headline percentage.

Clinical pregnancy is also not the final point in the attrition funnel.

The UK fertility regulator reported an average fresh-transfer pregnancy rate of 31% and a birth rate of 25%. Applying the same pregnancy-to-live-birth attrition to the HSE figures reduces the estimated live birth rate to 10% per IVF cycle started.

The headline figure is 30%.

The estimated live birth rate from the point where the IVF cycle began is 10%.

That is the figure a patient needs in order to understand the scale of attrition between starting treatment and taking home a baby.

The same denominator problem runs through the other treatment figures

The ICSI, frozen embryo transfer and IUI rates use the same narrowed view.

The ICSI pregnancy rate begins with embryo transfers, not the 1,020 cycles recorded as started in the detailed section of the report.

The frozen embryo transfer rate begins with transfers performed, not all 1,319 cycles started.

The IUI pregnancy rate begins with the 478 inseminations completed, not the 594 cycles started.

These figures measure what happened after a patient reached the final procedure.

They do not measure the outcome from the point treatment began.

That distinction should be made explicit wherever the rates are published. Otherwise, a patient reading “30% IVF pregnancy rate” could reasonably believe that approximately 30% of those who started IVF became pregnant.

The HSE’s own figures show that this is not what the percentage means.

The regional fertility hubs do not systematically count either outcome

The six regional fertility hubs recorded 435 clinical pregnancies during 2025.

But this was not systematic outcome tracking.

Of the 435 pregnancies, 291 were reported by patients themselves. The remaining 144 were identified through scans carried out within the hubs, usually incidentally during ovulation induction monitoring. The hubs do not routinely perform dedicated pregnancy confirmation scans as part of conservative management pathways.

In other words, a pregnancy is counted if the patient reports it or if it happens to be seen during care. Patients are not routinely followed to establish whether they became pregnant.

The report also does not record how many couples completed regional hub care and were discharged without succeeding.

So neither outcome is systematically measured.

The 435 pregnancies are not a complete pregnancy count, and there is no corresponding count of unsuccessful discharges. That means the report cannot show the success rate for couples entering the regional fertility hubs.

A total pregnancy count does not repair the missing patient pathway

The report states that 664 clinical pregnancies were recorded during 2025.

That figure is presented as evidence of an effective service.

But 664 pregnancies during one calendar year cannot be set against the 5,818 referrals accepted during that year.

They are not the beginning and end of the same patient journey.

The patients may have entered the service in different years. Some may have undergone several treatment procedures. Some patients referred in 2025 were still receiving care when the report closed.

A total pregnancy count measures activity during a period.

It does not show what proportion of couples completed the pathway pregnant or were discharged without succeeding.

Live birth is not the only missing outcome

The HSE acknowledges that it does not capture live birth outcomes.

That is a serious gap in assisted reproduction reporting because clinical pregnancy is not the outcome patients ultimately hope to take home.

But the missing information begins before live birth.

The fertility service should know whether the patient was pregnant when fertility care ended.

That does not require the regional fertility hub or fertility clinic to follow the patient throughout antenatal care. It requires a final fertility outcome to be recorded at discharge.

Pregnancy achieved.

Discharged without succeeding.

Live birth reporting would then show how many clinical pregnancies progressed to birth.

The report currently provides neither the complete fertility outcome nor the final birth outcome.

Patient-centred reporting starts with the patient

A patient-centred report would keep each couple connected to one pathway from accepted referral until fertility care ended.

Appointments, investigations, cancelled cycles, egg collections, embryo transfers and inseminations would remain attached to that patient record.

At the end of the reporting period, each couple would be recorded as:

Still receiving care.

Pregnant.

Discharged without succeeding.

The first category carries forward into the next reporting year. The other two provide the final fertility outcome.

Procedure pregnancy rates could still be reported because they show what happens once transfer or insemination takes place.

But they should sit alongside the patient outcome.

They cannot replace it.

Access is progress. Activity is not success.

Ireland’s public fertility service has given thousands of couples access to investigations and assisted reproduction that were previously unavailable through a national public pathway.

That matters.

But referrals, clinics and treatment cycles show what the service did.

They do not show whether the patient got what they came for.

Until the HSE reports how many couples achieve a pregnancy and how many are discharged without succeeding, its claim to provide a holistic, patient-centred fertility service has a patient-shaped hole in the middle.

I know you are excited and anxious to confirm your pregnancy and start planning for your future.

Right now the only question for you is when can I test after embryo transfer.

If you are approaching this wait after a previous failed transfer or pregnancy loss, the uncertainty can feel even more intense because you are carrying memory of how this stage unfolded before. After your embryo transfer, everything can feel very still on the outside — yet inside your body implantation activity is already beginning.

Implantation strengthens before pregnancy hormone levels become detectable

Implantation starts when your embryo begins attaching to the lining of your uterus. As this attachment strengthens, specialised cells on the outer layer begin producing the hormone hCG. This hormone is the earliest measurable signal that pregnancy is establishing.

hCG first rises in the bloodstream and only later becomes detectable in urine. Because of this, pregnancy tests cannot turn positive immediately after transfer.

A reliable result only appears once implantation has progressed far enough for hCG levels to rise beyond the detection threshold of the test. The exact timing of this process naturally varies from one transfer to another.

Embryo developmental stage influences when implantation signals appear

One important influence is the developmental stage of your embryo at transfer.

A Day-5 blastocyst has already reached a stage where implantation may begin relatively soon after transfer. In some cycles, early hormone production can begin within a few days, and a faint positive pregnancy test may appear from around five to seven days later.

A Day-3 embryo still needs time to continue developing before implantation begins. In these situations, measurable hCG often rises later — sometimes not until seven to ten days after transfer or beyond.

For this reason, clinics usually recommend waiting for the scheduled blood test. By this point, implantation has usually had enough time to stabilise, allowing hormone levels to rise in a way that gives a clearer indication of whether early pregnancy is progressing.

Early pregnancy test results often reflect biological timing rather than outcome

The period after embryo transfer can feel like suspended time. Testing very early often produces results that are difficult to interpret because implantation may still be in its earliest stages.

At this stage, attachment between your embryo and the uterine lining may still be developing, and early trophoblast signalling is only beginning to establish measurable hormone production.

A negative pregnancy test during these first days often reflects that hCG has not yet risen beyond the detection threshold of the test. Similarly, a faint or fluctuating positive result can occur when hormone levels are still close to this threshold while implantation continues to stabilise.

Differences in attachment timing, the pace at which early circulation develops, and natural variation in how quickly hormone levels rise all influence what becomes visible on a home pregnancy test. These early results therefore represent a snapshot within an unfolding biological process rather than a definitive indication of how the transfer will progress.

Implantation progression is shaped by the internal uterine environment

Although embryo stage affects when implantation begins, the internal environment of the uterus also plays an important role.

Endometrial blood supply, hormonal stability after transfer, and the wider metabolic and inflammatory state of the body can all influence how smoothly implantation develops.

These factors help determine how effectively your embryo can attach, establish early circulation and begin producing rising levels of hCG. This is why pregnancy test timelines can vary even when embryos are transferred on the same day or at the same developmental stage.

The testing window is also a phase where implantation is still stabilising

After embryo transfer, it is easy to become absorbed in watching for physical signs while waiting for pregnancy test results to become clearer.

During these early days, implantation is still working to secure stable attachment within the uterine lining.

Hormone signalling is only beginning to strengthen.
Early circulation to the developing implantation site is still becoming established.

At this stage, implantation stability depends heavily on regular glucose availability, adequate micronutrient supply and consistent uterine blood flow.

If these internal conditions fluctuate, implantation signalling can weaken before pregnancy hormone levels have risen enough to be clearly detected.

Providing structured nutritional preparation during this specific testing window helps support the physiological processes that allow implantation to consolidate more securely while early pregnancy is still establishing.

After fertilisation, implantation is the decisive biological phase in which pregnancy either begins to establish or does not progress.

Support implantation during this critical two-week window

What embryo grading explained means in IVF

Embryo grading explained helps you understand what AA, BB or 3BB actually mean on your IVF report.
These grades describe how the embryo looked in the laboratory — not whether pregnancy will establish after transfer.

Embryo grading is not a single universal system.
Different clinics use slightly different grading frameworks, but most are variations of the same underlying method for assessing blastocyst development.

The most commonly used system is the Gardner blastocyst grading system.

In this system, grading is made up of three parts:

The number (1–6) refers to the degree of blastocyst expansion.
This describes how far the embryo has developed at the time it is assessed.

1–2 → early blastocyst (limited expansion)
3 → full blastocyst
4 → expanded blastocyst
5 → hatching blastocyst
6 → fully hatched blastocyst

Higher numbers indicate more advanced development at that moment in time.

The first letter (A–C) refers to the inner cell mass (ICM).
This group of cells later forms the fetus.

A → tightly packed, clearly defined cells
B → looser grouping, moderate organisation
C → fewer cells, less defined structure

The second letter (A–C) refers to the trophectoderm (TE).
These outer cells contribute to the placenta and are involved in implantation.

A → many cells forming a cohesive layer
B → fewer cells, less organised
C → sparse or irregular distribution

A grading such as 4AA therefore describes an expanded blastocyst with strong fetal and placental cell organisation.
A 3BB indicates a slightly earlier stage with moderate cellular structure.
A 5BC reflects a more advanced stage of expansion but with less cohesive cellular appearance.

Some clinics simplify this system into “good / fair / poor” categories or group embryos into top / average / low quality.
Others may report only the expansion stage or use modified lettering systems.

Day-3 embryo grading: cell number, symmetry and fragmentation

In earlier-stage embryos (commonly assessed around day 3), grading focuses on how the embryo is dividing.

Cell number reflects how many cells are present at that stage.
Embryos that are dividing in a coordinated way typically reach a predictable cell number by day 3, while slower or faster division can indicate variation in developmental timing.

Symmetry of division refers to how evenly those cells are sized.
When cells are of similar size, this suggests coordinated early development. Greater variation in cell size can indicate that division has occurred less synchronously at that stage.

Fragmentation describes small fragments of cellular material that appear between the cells.
These fragments are not functioning cells and are thought to result from uneven division or cellular stress during early development.

Lower levels of fragmentation are generally associated with more organised development, while higher levels may reflect reduced cellular cohesion at that point in time.
Fragmentation is usually described as a percentage of the embryo’s overall structure.

These features are considered together to give an overall impression of how early development is progressing, rather than being interpreted in isolation.

These may be described based on:

• number of cells
• symmetry of division
• degree of fragmentation

For example, an 8-cell embryo with minimal fragmentation is typically considered to be developing in a coordinated way at that stage.

Although the terminology can vary, all grading systems are attempting to describe the same thing:
how the embryo looks at a specific point in development.

What embryo grading is designed to estimate

Embryo grading describes appearance in the laboratory. Implantation determines what happens next.

Embryo grading is therefore a visual classification system, not a functional test.
It does not measure implantation directly or determine whether pregnancy will establish after transfer.
It provides a structured way to compare developmental appearance within a given cohort of embryos.

Understanding the grading language allows you to interpret your clinic report more clearly, particularly when multiple embryos are available and selection decisions are being made.

Why embryo grading cannot predict implantation with certainty

Although embryo grading describes how development appeared in the laboratory, the biological processes through which pregnancy begins to establish are part of the wider physiology of embryo implantation.

Implantation has 5 distinct phases

Each phase must complete successfully for pregnancy to progress. The process is dependent on metabolic stability and nutrient availability which can be supported with targeted nutrition. Your clinic has done everything meticulously up to this point, now you can continue supporting your embryo to progress.

The Now Baby FET Implantation Meal Plan is professionally created to support both metabolic stability and targeted nutrient availability during the critical two week wait.

Get the FET Implantation Support Meal Plan